Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors.
El-Khoueiry AB, Clarke J, Neff T, Crossman T, Ratia N, Rathi C, Noto P, Tarkar A, Garrido-Laguna I, Calvo E, Rodón J, Tran B, O'Dwyer PJ, Cuker A, Abdul Razak AR. El-Khoueiry AB, et al. Br J Cancer. 2023 Aug;129(2):309-317. doi: 10.1038/s41416-023-02276-0. Epub 2023 May 26. Br J Cancer. 2023. PMID: 37237172 Free PMC article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 36542251
Gene expression levels of epidermal growth factor receptor, survivin, and vascular endothelial growth factor as molecular markers of lymph node involvement in patients with locally advanced rectal cancer.
Yang D, Schneider S, Azuma M, Iqbal S, El-Khoueiry A, Groshen S, Agafitei D, Danenberg KD, Danenberg PV, Ladner RD, Lenz HJ. Yang D, et al. Clin Colorectal Cancer. 2006 Nov;6(4):305-11. doi: 10.3816/CCC.2006.n.049. Clin Colorectal Cancer. 2006. PMID: 17241515
Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent.
Wakatsuki T, Stintzing S, Zhang W, Yang D, Azuma M, Ning Y, Yamauchi S, Matsusaka S, Volz NB, Sunakawa Y, Koizumi W, Watanabe M, Barzi A, El Khoueiry AB, Shah MA, Lenz HJ. Wakatsuki T, et al. Pharmacogenet Genomics. 2014 Nov;24(11):539-47. doi: 10.1097/FPC.0000000000000087. Pharmacogenet Genomics. 2014. PMID: 25203737 Free PMC article.
Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy.
Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O, Velasquez L, Hayes W, Feltquate D, Syed S, Ford S, Kollia G, Galbraith S, Nuyten DS. Garrett CR, et al. Br J Cancer. 2011 Jun 28;105(1):44-52. doi: 10.1038/bjc.2011.182. Epub 2011 May 31. Br J Cancer. 2011. PMID: 21629245 Free PMC article. Clinical Trial.
Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.
Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM. Koczywas M, et al. Br J Cancer. 2014 Dec 9;111(12):2268-74. doi: 10.1038/bjc.2014.554. Epub 2014 Oct 28. Br J Cancer. 2014. PMID: 25349975 Free PMC article. Clinical Trial.
101 results